BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P.
Dawson SJ, et al. Among authors: green ar.
Br J Cancer. 2010 Aug 24;103(5):668-75. doi: 10.1038/sj.bjc.6605736. Epub 2010 Jul 27.
Br J Cancer. 2010.
PMID: 20664598
Free PMC article.